Effects of Q10 supplementation in type II diabetes

Effect of coenzyme Q10 supplementation on serum adiponectin-to-leptin ratio, 8-isoprostane and malondialdehyde in female patients with type 2 diabetes

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016081525949N3

Enrollment

Registered

2016-08-27

Start date

2016-07-26

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetic. Non-insulin-dependent diabetes mellitus

Interventions

Intervention 1: Control group: One capsule placebo cellulose acetate (100 mg) per day for 12 weeks. Intervention 2: Intervention group: One capsule coenzyme Q10 (100 mg) per day for 12 weeks.

Placebo

Treatment - Drugs

Control group: One capsule placebo cellulose acetate (100 mg) per day for 12 weeks.

Intervention group: One capsule coenzyme Q10 (100 mg) per day for 12 weeks.

Eligibility

Sex/Gender

Female

Age

30 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients that have been suffered type 2 diabetes for more than 2 years and that have not consumed vitamin and mineral supplements during the last three months. Exclusion criteria: changing in dosage of glucose lowering medications, physical activity and diet during the intervention; any chronic renal, hepatic, thyroid, haematic and gastrointestinal disorders; hormone therapy; insulin therapy; alcoholism; smoking; pregnancy; lactation and using anticoagulants, diuretics and ß blockers.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Fasting glucose. Timepoint: Before and after 12 weeks of intervention. Method of measurement: Colorimetric.;HbA1C. Timepoint: Before and after 12 weeks of intervention. Method of measurement: Chromatoghraphy.;Fasting insulin. Timepoint: Before and after 12 weeks of intervention. Method of measurement: ELISA.;Coenzyme Q10. Timepoint: Before and after 12 weeks of intervention. Method of measurement: Chromatoghraphy.;Leptin. Timepoint: Before and after 12 weeks of intervention. Method of measurement: ELISA.;Adiponectin. Timepoint: Before and after 12 weeks of intervention. Method of measurement: ELISA.;8-isoprostane. Timepoint: Before and after 12 weeks of intervention. Method of measurement: ELISA.;Malondialdehyde. Timepoint: Before and after 12 weeks of intervention. Method of measurement: Spectrophotometric.	—

Measure

Time frame

Fasting glucose. Timepoint: Before and after 12 weeks of intervention. Method of measurement: Colorimetric.;HbA1C. Timepoint: Before and after 12 weeks of intervention. Method of measurement: Chromatoghraphy.;Fasting insulin. Timepoint: Before and after 12 weeks of intervention. Method of measurement: ELISA.;Coenzyme Q10. Timepoint: Before and after 12 weeks of intervention. Method of measurement: Chromatoghraphy.;Leptin. Timepoint: Before and after 12 weeks of intervention. Method of measurement: ELISA.;Adiponectin. Timepoint: Before and after 12 weeks of intervention. Method of measurement: ELISA.;8-isoprostane. Timepoint: Before and after 12 weeks of intervention. Method of measurement: ELISA.;Malondialdehyde. Timepoint: Before and after 12 weeks of intervention. Method of measurement: Spectrophotometric.

—

Secondary

Measure	Time frame
BMI. Timepoint: Before and after 12 weeks of intervention. Method of measurement: Formula.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Ali Khosrowbeygi

Arak University of Medical Sciences

a.khosrowbeygi@arakmu.ac.ir; khosrowbeygi@yahoo.com+98 86 3417 3645

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026